Abstract
Susceptibilities of 98 clinical isolates of Pseudomonas aeruginosa, including 33 strains with known mechanisms of amikacin resistance, were tested by the agar dilution method against 10 beta-lactam drugs. Ceftazidime, imipenem, and cefsulodin had the greatest activity, regardless of the aminoglycoside susceptibilities. The strains which were highly resistant to amikacin appeared to be less susceptible to some beta-lactam drugs, especially if their resistance was related to amikacin-inactivating enzymes; statistical significance, however, was observed for aztreonam only.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Appel G. B., Neu H. C. The nephrotoxicity of antimicrobial agents (second of three parts). N Engl J Med. 1977 Mar 31;296(13):722–728. doi: 10.1056/NEJM197703312961305. [DOI] [PubMed] [Google Scholar]
- Baltch A. L., Griffin P. E. Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients. Am J Med Sci. 1977 Sep-Oct;274(2):119–129. [PubMed] [Google Scholar]
- Baltch A. L., Hammer M., Smith R. P., Sutphen N. Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance. J Lab Clin Med. 1979 Aug;94(2):201–214. [PubMed] [Google Scholar]
- Barry A. L., Jones R. N., Thornsberry C. Cefsulodin: antibacterial activity and tentative interpretive zone standards for the disk susceptibility test. Antimicrob Agents Chemother. 1981 Oct;20(4):525–529. doi: 10.1128/aac.20.4.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Matzkowitz A. J., Baltch A. L., Smith R. P., Sutphen N. T., Hammer M. C., Conroy J. V. In vitro comparison of N-formimidoyl thienamycin (MK0787) and Azlocillin with three aminoglycosides and ticarcillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Apr;21(4):685–687. doi: 10.1128/aac.21.4.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Jan;21(1):11–18. doi: 10.1128/aac.21.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Labthavikul P. In vitro activity and beta-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents. Antimicrob Agents Chemother. 1983 Aug;24(2):227–232. doi: 10.1128/aac.24.2.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Preheim L. C., Penn R. G., Sanders C. C., Goering R. V., Giger D. K. Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 1982 Dec;22(6):1037–1041. doi: 10.1128/aac.22.6.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ribner B. S., Raeder R., Becker T. M., Freimer E. H. Treatment of serious infections with moxalactam. Am J Med. 1983 Mar;74(3):396–400. doi: 10.1016/0002-9343(83)90957-9. [DOI] [PubMed] [Google Scholar]
- Scribner R. K., Marks M. I., Weber A. H., Tarpay M. M., Welch D. F. Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother. 1982 Jun;21(6):939–943. doi: 10.1128/aac.21.6.939. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sutphen N. T., Baltch A. L., Conroy J. V., Hammer M. C., Smith R. P. Comparative inhibitory and bactericidal activities of moxalactam and seven other antibiotics against 520 clinical isolates including 65 multi-drug resistant strains. J Antimicrob Chemother. 1982 Jul;10(1):11–24. doi: 10.1093/jac/10.1.11. [DOI] [PubMed] [Google Scholar]